<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" version="2.0" nsmap="{'media': 'http://search.yahoo.com/mrss/'}"><channel><title>Raichur News Feed</title><link>https://news.google.com/rss/search?q=raichur&amp;hl=en-US&amp;gl=US&amp;ceid=US:en</link><description>Latest news about Raichur</description><language>en-US</language><item><title>Shilpa Medicare arm gets 1 UFSDA observation for Raichur Unit</title><link>https://medicaldialogues.in/news/industry/pharma/shilpa-medicare-arm-gets-1-ufsda-observation-for-raichur-unit-144520</link><description>&lt;![CDATA[Karnataka: Shilpa Medicare has announced that the United States Food and Drugs Administration (USFDA) has concluded an inspection with one observation at Unit-1 of Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of the Company located at Raichur.

The facility was inspected from March 3-7, 2025.

"On conclusion of inspection, we received 1 (one) observation in form 483, which is procedural in nature," the Company stated.

An FDA Form 483 is issued to firm management at the conclusi...]]&gt;</description><pubDate>2025-03-08</pubDate><author>Ruchika Sharma, Written, Medically Reviewed, Dr. Kamal Kant Kohli</author><media:content url="https://medicaldialogues.in/h-upload/2023/01/10/197259-shilpa-medicare-1.jpg" medium="image" /></item></channel></rss>